• Product NameNeratinib(HKI-272)
• Brief DescriptionInhibitors
• Purification96.17%
• Biological ActivityNeratinib (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor with IC50 of 59 nM and 92 nM for HER2 and EGFR, respectively.
• Target NameEGFR inhibitor; HER inhibitor; PDK inhibitor; Src inhibitor; VEGFR inhibitor
• CAS No. 698387-09-6
• Calculated MW 557.04
• Formulation C30H29ClN6O3
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/CN(C)C
  Pathways:Angiogenesis; PI3K/Akt/mTOR signaling; JAK/STAT signaling; Tyrosine Kinase/Adaptors
  Receptor:EGFR; HER2; PDK1; Src; VEGFR2?(KDR)
  Boling pt:
  Melting pt:
  Solubility:DMSO: 2 mg/mL (3.59 mM)
  Appearance:Off-white Color Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Schwab CL, et al. Gynecol Oncol. 2014 Oct;135(1):142-8.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting